IGCP5陆7地震考古钻探项目最新动态音讯,NAACL2018协办征文消息

IGCP567地震考古商讨项目最新动态新闻

“目录号: HY-14171

http://acl2018.org/news/joint-call-for-tutorials

迎接有对于地震考古商量和喇家遗址远古地震感兴趣的年轻情侣立时与大家关系

Metabolic
Enzyme/ProteaseAutophagy-

mgm美高梅,First Joint Call for Tutorial Proposals

The Association for Computational Linguistics (ACL), the International
Conference on Computational Linguistics (COLING), the Conference on
Empirical Methods in Natural Language Processing (EMNLP), and the North
American Chapter of the Association for Computational Linguistics
(NAACL) invite proposals for tutorials to be held in conjunction with
ACL 2018, COLING 2018, EMNLP 2018, or NAACL 2018. We seek proposals for
tutorials in all areas of computational linguistics, broadly conceived
to include related disciplines such as linguistics, speech, information
retrieval and multimodal processing. We particularly welcome:
tutorials that cover advances in newly emerging areas not previously
covered in any ACL/COLING/EMNLP/NAACL related tutorial, or
tutorials that provide introductions into related fields that are
potentially relevant for the CL community (e.g., bioinformatics, social
media, human language processing, machine learning techniques).

Tutorials will be held at one of the following conference venues:
ACL 2018 is the 56th
Annual Meeting of the Association for Computational Linguistics. It will
be held in Melbourne, Australia on July 15–20, 2018. The ACL tutorials
will be held on July 15th.
COLING 2018 is the
27th Biennial International Conference on Computational Linguistics
(COLING). It will be held in Santa Fe, New Mexico, USA on August 20-25,

  1. The COLING tutorials will be held on August 20-21.
    EMNLP 2018 is the SIGDAT conference on Empirical Methods in Natural
    Language Processing (EMNLP). EMNLP will be held later in 2018 (after the
    other three conferences). Exact details on dates and venue for EMNLP
    tutorials will be announced soon.
    NAACL 2018 is the
    16th Annual Meeting of the North American Chapter of the Association for
    Computational Linguistics (NAACL). It will be held in New Orleans,
    Louisiana, USA, June 1-6, 2018. The NAACL tutorials will be held on June
    1.

Remuneration
Information on the payment for tutorial instructors can be found in the
Tutorial Teacher Payment
Policy
Please note: remuneration for tutorial presenters is fixed according to
the above policy and does not cover registration fees for the main
conference.

Submission Details
Proposals should be submitted as PDF documents. Proposals should
contain:
A title and brief description of the tutorial content and its relevance
to the CL community (not more than 2 pages).

A brief outline of the tutorial structure showing that the tutorial’s
core content can be covered in a three-hour slot (including a coffee
break). In exceptional cases six-hour tutorial slots are available as
well.

The names, affiliations, email addresses and websites of the tutorial
instructors, including a one-paragraph statement of their research
interests and areas of expertise.

Please provide an estimate of the audience size for the tutorial. If the
same or a similar tutorial has been given before, a note specifying
where previous versions of the tutorial were given, how many attendees
were there, and how many attendees the tutorial attracted.

A description of special requirements for technical equipment (e.g.,
internet access).

A note specifying which venue(s) (ACL/COLING/EMNLP/NAACL) would be
acceptable and/or preferable. Please include a description of any
constraints that might make the tutorial compatible with only one of
these events, logistically, thematically, or otherwise.

Tutorial proposals should be submitted online using the START
system
Proposals will be reviewed jointly by the Tutorial Co-Chairs of the four
conferences.
Tutorial Speaker Responsibilities
Accepted tutorial speakers will be notified by February 1, 2018. They
must then provide abstracts of their tutorials for inclusion in the
conference registration material by the specific conference deadlines.
The description should be in two formats: an ASCII version that can be
included in email announcements and published on the conference website,
and a PDF version for inclusion in the electronic proceedings (detailed
instructions will be provided). Tutorial speakers must provide tutorial
materials, at least containing copies of the course slides as well as a
bibliography for the material covered in the tutorial, by the deadlines
specified for the four conferences, to be determined later.

 

Bexarotene (Targretin)是维甲酸X受体(科雷傲X本田UR-V)激动剂,可职能于CTCL。

Important Dates

 

RAR/RXRAutophagy

Shared dates:

Submission deadline for tutorial proposals: January 20th, 2018
Notification of acceptance: February 1, 2018

MEETINGS

连带产品

COLING2018 CCF 推荐的B类

Important Dates
Mentoring program submission deadline Feb 16, 2018
Submission deadline (main conference) Mar 16, 2018
Notifications May 17, 2018

· On 22 February 2012 IGCP will celebrate its 40th
Anniversary
at the UNESCO
Headquarters in Paris. Two of our co-leaders will actively participate
at this meeting. Iain Stewart (University of Plymouth, U.K.) will focus
on the importance of Geosciences for Society and moderate a debate on
the prospective vision for the future of IGCP. Manuel Sintubin
(Katholieke Universiteit Leuven, Belgium) will reflect on the role of
IGCP in geohazard mitigation
based on the success of IGCP567.

Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB
203580-SP600125-U0126-Enzalutamide-Actinomycin
D-Olaparib-Doxorubicin
hydrochloride-Dorsomorphin
dihydrochloride-Mitomycin
C-Bortezomib-

Tutorial Chairs

 

生物活性

ACL:

Yoav Artzi, Cornell University, USA
Jacob Eisenstein, Georgia Institute of Technology, USA

·At the 2012 Annual Meeting of the Seismological Society of
America
(17-19 April, 2012,
San Diego, California): Earthquakes and Tsunamis at Caostal
Archaeological Sites
. You find details in the following announcement
(pdf
). Abstract submission deadline is 11 January
2012
.

Description

COLING:

Pascale Fung, UST, Hong Kong
Donia Scott, Sussex, UK
Marilyn Walker, University of California Santa Cruz, USA

 

Bexarotene (Targretin) is a selective RXR agonist approved for the
treatment of CTCL.IC50 value:Target: retinoid X receptorExposure of
NSCLC cell lines to bexarotene as a single agent had modest growth
inhibitory effects (at > 1 μM). However, exposure of several NSCLC
lines to bexarotene (1–3 μM) produced significant decreases in the
expression of EGFR, Her-2 and TGF mRNA and protein. EGF levels were also
decreased to a much lesser degree.

EMNLP

To be determined
NAACL-HLT:
Mohit Bansal, U North Carolina, USA
Rebecca Passonneau, Penn State U, USA

Please send enquiries concerning ACL/COLING/EMNLP/NAACL 2018 tutorials
to the workshop organizers at
acl-coling-emnlp-naacl-tutorials@googlegroups.com.

International Conference on Document Analysis and Recognition (ICDAR)
CCF C类推荐
CoNLLConference on Natural Language Learning CCF C类

·At the 34th International Geological
Congress (IGC)
, from 2 to 10
August 2012
at Brisbane, Queensland, Australia a special session is
convened by Patrick Nunn (Australia), Bruce McFadgen (New Zealand), Iain
Stewart (U.K.) and Manuel Sintubin (Belgium) on Natural Hazards and
Ancient
Societies
.
Abstract submission deadline is 17 February 2012.

Clinical Trial

 

NCT00153842

·In November 2012 we are furthermore planning an international workshop
Shakin’ them off? Interdisciplinary perspectives on Minoan
Earthquakes
, convened by Simon Jusseret (Université Catholique de
Louvain, Belgium) and Manuel Sintubin (Katholieke Universiteit Leuven,
Belgium), which will take place in Leuven (Belgium).

Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand
Pharmaceuticals

 

Carcinoma, Non-small-cell Lung

For both conferences IGCP567 will most probably (depending on our
funding) be able to offer travel grants.

August 2001

 

Phase 1-Phase 2

·At the EGU meeting (20-24 April
2012, Vienna, Austria) Matthieu Ferry (Géosciences Montpellier, France)
and Kris Vanneste (ROB, Belgium) convene a session on Earthquake
Geology
.
Abstract submission deadline is 17 January 2012.

NCT00615784

 

Abramson Cancer Center of the University of Pennsylvania

·The 3rd Workshop on Paleoseismology and
Archaeoseismology

will be held in Morelia, Mexico from 1 to 8 November 2012.
More information will follow soon on the
http://www.acambay1912.org.

Acute Myeloid Leukemia

 

January 2008

PUBLICATIONS

Phase 2

 

NCT01504490

Following our 2nd INQUA-IGCP567 International Workshop on
Active Tectonics, Earthquake Geology, Archaeology and
Engineering
,
held from 18 to 24 September 2011 in Corinth, Greece, Andreas Vött
(University of Mainz, Germany) is preparing a special volume on in the
Zeitschrift für Geomorphologie. This is a peer-review ISI-indexed
journal and hosted up to now three special volumes on tsunamis. If you
are interested to contribute to this volume, please contact Andreas Vött
(voett@uni-mainz.de).

Georgetown University-Daiichi Sankyo Inc.

 

Solid Tumors-Lymphoma-Multiple Myeloma

International Geoscience Programme
IGCP 567 Earthquake Archaeology

December 2011

De wetenschap van de Aarde. Over een levende
planeet

Phase 1


NCT00125372

 

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Disclaimer:

Carcinoma, Non-small-cell Lung

December 2005

NCT00845351

University of Virginia

Cushing’s Disease

November 2008

Phase 1-Phase 2

NCT01782742

The Cleveland Clinic

Alzheimer’s Disease

February 2013

Phase 2

NCT01116622

Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand
Pharmaceuticals

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and
Esophagus)

April 2003

Phase 1

NCT00055991

Baylor Breast Care Center-National Cancer Institute (NCI)

Breast Cancer

September 2001

Phase 1

NCT00125359

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

August 2005

Phase 2

NCT02061878

ReXceptor, Inc.

Alzheimer’s Disease

August 2014

Phase 1

NCT01007448

Valeant Pharmaceuticals International, Inc.

Refractory Cutaneous T-cell Lymphoma

December 2009

Phase 4

NCT00660231

University College, London

Lymphoma

March 2008

Phase 2

NCT01001143

Washington University School of Medicine

Leukemia, Myeloid, Acute

May 2010

Phase 1

NCT00316030

Abramson Cancer Center of the University of Pennsylvania

AML-Acute Myeloid Leukemia

January 2004

Phase 1

NCT00411632

M.D. Anderson Cancer Center-United States Department of Defense

Lung Cancer

November 2006

Phase 2

NCT00306969

Boston University-Ligand Pharmaceuticals

Cutaneous T-Cell Lymphoma

December 2001

Phase 1-Phase 2

NCT00535574

Beersheva Mental Health Center

Schizophrenia

November 2008

Phase 3

NCT01578499

Millennium Pharmaceuticals, Inc.-Seattle Genetics, Inc.-Takeda

Primary Cutaneous Anaplastic Large Cell Lymphoma-Mycosis
Fungoides-Cutaneous T-Cell Lymphoma

August 2012

Phase 3

NCT00255801

Memorial Sloan Kettering Cancer Center-National Cancer Institute
(NCI)-Tibotec Pharmaceutical Limited-M.D. Anderson Cancer Center-New
York University School of Medicine-Hackensack University Medical
Center-Roswell Park Cancer Institute

Lymphoma

November 2005

Phase 2

NCT00178841

Vanderbilt University

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome

June 2005

Phase 2

NCT00141947

Beersheva Mental Health Center-Stanley Medical Research Institute

Schizophrenia

September 2005

Phase 3

NCT00151008

University of Medicine and Dentistry of New Jersey-Ligand
Pharmaceuticals-Rutgers, The State University of New Jersey

Psoriasis

November 2003

Phase 2

NCT01134341

Spectrum Pharmaceuticals, Inc

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome-Primary
Cutaneous Anaplastic Large Cell Lymphoma

March 2010

Phase 1

NCT00322296

Fox Chase Cancer Center-Ligand Pharmaceuticals

Parapsoriasis

April 2001

Phase 2

NCT00003752

Ligand Pharmaceuticals-National Cancer Institute (NCI)

Breast Cancer

October 1998

Phase 2

NCT00056056

European Organisation for Research and Treatment of Cancer – EORTC

Lymphoma

January 2003

Phase 3

NCT00127101

Merck Sharp & Dohme Corp.

Lymphoma

September 2005

Phase 1

NCT00718770

University of Colorado, Denver-American Cancer Society, Inc.-Eisai Inc.

Thyroid Cancer

November 2008

Early Phase 1

NCT00050960

Eisai Inc.

Non-small Cell Lung Cancer

May 2002

Phase 3

NCT00050973

Eisai Inc.

Non-small Cell Lung Cancer

Phase 3

NCT00238628

Stanford University-Ligand Pharmaceuticals-AstraZeneca

Lung Cancer

April 2004

Phase 1-Phase 2

NCT00030849

Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)

Lymphoma

October 2001

Phase 2

NCT00534898

Beersheva Mental Health Center

Schizophrenia-Schizoaffective Disorder-Cognition

Phase 3

NCT00002212

Ligand Pharmaceuticals-NIH AIDS Clinical Trials Information Service

Sarcoma, Kaposi-HIV Infections

Phase 2

NCT00425477

Sidney Kimmel Comprehensive Cancer Center-National Cancer Institute
(NCI)

Leukemia-Myelodysplastic Syndromes-Myelodysplastic/Myeloproliferative
Diseases

November 2006

Phase 2

NCT00514293

Raghu Nandan, M.D., Inc-National Cancer Institute (NCI)

Lung Cancer

January 2007

Phase 2

NCT00030589

Millennix-National Cancer Institute (NCI)

Lymphoma

February 2001

Phase 2

NCT00153842

Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand
Pharmaceuticals

Carcinoma, Non-small-cell Lung

August 2001

Phase 1-Phase 2

NCT00615784

Abramson Cancer Center of the University of Pennsylvania

Acute Myeloid Leukemia

January 2008

Phase 2

NCT01504490

Georgetown University-Daiichi Sankyo Inc.

Solid Tumors-Lymphoma-Multiple Myeloma

December 2011

Phase 1

NCT00125372

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

December 2005

NCT00845351

University of Virginia

Cushing’s Disease

November 2008

Phase 1-Phase 2

NCT01782742

The Cleveland Clinic

Alzheimer’s Disease

February 2013

Phase 2

NCT01116622

Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand
Pharmaceuticals

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and
Esophagus)

April 2003

Phase 1

NCT00055991

Baylor Breast Care Center-National Cancer Institute (NCI)

Breast Cancer

September 2001

Phase 1

NCT00125359

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

August 2005

Phase 2

NCT02061878

ReXceptor, Inc.

Alzheimer’s Disease

August 2014

Phase 1

NCT01007448

Valeant Pharmaceuticals International, Inc.

Refractory Cutaneous T-cell Lymphoma

December 2009

Phase 4

You can leave a response, or trackback from your own site.

Leave a Reply

网站地图xml地图